美国血液透析患者脓毒症发病率及危险因素
基于美国肾脏数据系统2006至2014年870571例初始透析患者,29.8%发生脓毒症,导管和移植物动静脉内瘘的脓毒症风险显著高于自体动静脉内瘘,且脓毒症与死亡率增加相关。
要点
- 导管和移植物动静脉内瘘的脓毒症发生率高于自体动静脉内瘘
- 脓毒症与死亡风险增加约三倍独立相关
- 脓毒症发生后,自体动静脉内瘘患者死亡率低于移植物和导管
核心结论
- 透析患者脓毒症风险与血管通路类型明确相关,并与死亡率大幅增加相关。
研究设计与样本
- 回顾性队列研究,纳入美国肾脏数据系统2006年1月1日至2014年12月31日期间870571例初始血液透析的终末期肾病患者。
主要发现
- 29.8%(259686例)患者发生脓毒症,导管31.2%、移植物30.6%高于自体动静脉内瘘22.9%(P < .001)。
- 脓毒症发生率为12.66例/100人年,导管13.86、移植物11.49、自体动静脉内瘘8.03例/100人年。
- 脓毒症患者较无脓毒症者年龄略大(65.09±14.49岁 vs 63.24±15.17岁),肥胖、充血性心力衰竭、外周动脉疾病和糖尿病比例更高(均P < .001)。
- 调整混杂后,3年时移植物(HR 1.35,95%CI 1.31-1.40)和导管(HR 1.80,95%CI 1.77-1.84)较自体动静脉内瘘更易发生脓毒症(均P < .001)。
- 脓毒症与死亡 odds 增加三倍相关(OR 3.16,95%CI 3.11-3.21,P < .001)。
关键数值与推荐
- 脓毒症发生率:总体12.66例/100人年,导管13.86、移植物11.49、自体动静脉内瘘8.03例/100人年。
- 3年脓毒症风险:移植物 vs 自体动静脉内瘘 HR 1.35(95%CI 1.31-1.40),导管 vs 自体动静脉内瘘 HR 1.80(95%CI 1.77-1.84),均P < .001。
- 脓毒症与死亡关联:OR 3.16(95%CI 3.11-3.21,P < .001)。
- 脓毒症后1年死亡:移植物 vs 自体动静脉内瘘 HR 1.21(95%CI 1.15-1.28,P < .001),导管 vs 自体动静脉内瘘 HR 1.94(95%CI 1.88-2.00,P < .001)。
临床怎么用
- 优先采用自体动静脉内瘘作为初始透析通路,以降低脓毒症发生率和改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sepsis is one the most serious and life-threatening complication in patients with chronic hemodialysis (HD) access. Arteriovenous fistula (AVF) use is associated with a lower risk of infection. However, several prior studies identified significantly higher number of patients initiating HD using a catheter (HC) or arteriovenous graft (AVG). The aim of this study was to use a large national renal database to report the incidence and risk factors of sepsis in patients with end-stage renal disease (ESRD) initiating HD access using AVF, AVG, or HC in the United States. METHODS: All patients with ESRD initiating HD access (AVF, AVG, HC) between January 1, 2006, and December 31, 2014, in United States Renal Data System were included. International Classification of Diseases, 9th edition-Clinical Modification diagnosis code (038x, 790.7) was used to identify patients who developed first onset of sepsis during follow-up. Standard univariate (Students t-test, χ2, and Kaplan-Meier) and multivariable (logistic/Cox regression) analyses were performed as appropriate. RESULTS: A total of 870,571 patients were identified, of whom, 29.8% (n = 259,686) developed sepsis. HC (31.2%) and AVG (30.6%) were associated with a higher number of septic cases compared with AVF (22.9%; P < .001). The incident rate of sepsis was 12.66 episodes per 100 person-years. It was the highest among HC vs AVG vs AVF (13.86 vs 11.49 vs 8.03 per 100 person-years). Patients with sepsis were slightly older (mean age 65.09 ± 14.49 years vs 63.24 ± 15.17 years) and had higher number of comorbidities including obesity (40.7% vs 37.7%), congestive heart failure (36.6% vs 30.8%), peripheral arterial disease (15.6% vs 12.4%), and diabetes (59.6% vs 53.5%) (all P < .001). After adjusting for potential confounders, compared with AVF, patients with AVG (hazard ratio [HR], 1.35 [95% confidence interval [CI], 1.31-1.40) and HC (HR, 1.80 [95% CI, 1.77-1.84) were more likely to develop sepsis at 3 years (both P < .001). Compared with patients with no sepsis, sepsis was associated with a three-fold increase the odds of mortality (odds ratio, 3.16; 95% CI, 3.11-3.21; P < .001). Additionally, in patients who developed sepsis, AVF use was associated with significantly lower mortality compared with AVG and HC (73.7% vs 78.7% vs 78.0%; P < .001). After adjusting for significant covariates, compared with AVF, mortality at 1 year after sepsis was 21% higher in AVG (HR, 1.21; 95% CI, 1.15-1.28; P < .001) and nearly doubled in HC (HR, 1.94; 95% CI, 1.88-2.00; P < .001). CONCLUSIONS: Sepsis risk in HD patients is clearly related to access type and is associated with dramatic increase in mortality. Initiating HD access with AVF to meet the National Kidney Foundation Kidney Disease Outcomes Quality recommendations should be implemented to reduce the incidence of sepsis and improve survival in patients with ESRD.
引用
- Locham S, Naazie I, Canner J, et al. Incidence and risk factors of sepsis in hemodialysis patients in the United States. J Vasc Surg. 2020. PMID: 32707386. doi:10.1016/j.jvs.2020.06.126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。